Get the Stockscreener App
13.96
0.36%
0.05
Jade Biosciences Inc stock is traded at $13.96, with a volume of 397.77K.
It is up +0.36% in the last 24 hours and down -12.75% over the past month.
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$13.91
Open:
$14.23
24h Volume:
397.77K
Relative Volume:
1.33
Market Cap:
$688.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.72%
1M Performance:
-12.75%
6M Performance:
+79.43%
1Y Performance:
+0.00%
1-Day Range:
$13.88
$14.34
1-Week Range:
$13.57
$15.00
52-Week Range:
$6.565
$17.71
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
(781) 312-3013
Address
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
13.96 | 685.96M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
Jade Biosciences Stock Quote, Share Price, News and Analysis - Longbridge
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears - Defense World
JBIO Should I Buy - Intellectia AI
JBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oppenheimer 36th Healthcare Life Sciences Conference: Spotlight On LGND, PHAR, CRBP, Among Others - RTTNews
Chipmakers Recap: Is Jade Biosciences Inc a stock for growth or value investors2025 Top Gainers & Long-Term Investment Growth Plans - baoquankhu1.vn
Can Jade Biosciences Inc. expand its profit marginsWeekly Profit Recap & Safe Entry Zone Tips - mfd.ru
Jade Biosciences (JBIO) grants RSUs and 247,500-share option to officer - Stock Titan
Weekly Earnings: Is Jade Biosciences Inc a speculative investmentJuly 2025 Spike Watch & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Jade Biosciences (NASDAQ:JBIO) Shares Gap UpHere's Why - MarketBeat
Jade Biosciences, Inc. (NASDAQ:JBIO) Short Interest Update - MarketBeat
Aug Sentiment: Is Jade Biosciences Inc a speculative investment2025 Top Gainers & Long-Term Investment Growth Plans - baoquankhu1.vn
Jade Biosciences (NASDAQ:JBIO) Trading Up 8.1%What's Next? - MarketBeat
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know - MSN
Jade Biosciences (NASDAQ:JBIO) Stock Price Down 5.3%Here's What Happened - MarketBeat
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock - MSN
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue - Finviz
Short Interest in Jade Biosciences, Inc. (NASDAQ:JBIO) Increases By 47.9% - MarketBeat
Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Breakout Watch: What is AvePoint Incs TAM Total Addressable MarketMarket Trend Report & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
JBIO: Advancing novel autoimmune therapies with strong data, market potential, and rapid clinical timelines - TradingView
Valuation Update: What is the PEG ratio of Jade Biosciences IncJuly 2025 PostEarnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Jade Biosciences (NASDAQ:JBIO) Trading Down 4.8%Should You Sell? - MarketBeat
Published on: 2026-01-10 20:20:04 - ulpravda.ru
How risky is Jade Biosciences Inc. stock nowPortfolio Profit Report & Fast Entry and Exit Trade Plans - Улправда
Will Jade Biosciences Inc. stock rally after Fed decisionsJuly 2025 Final Week & Real-Time Chart Pattern Alerts - Улправда
How Jade Biosciences Inc. stock reacts to global recession fearsFit and Size Notes & quick comparison of popular models - Улправда
Equities Analysts Offer Predictions for JBIO FY2025 Earnings - MarketBeat
How Jade Biosciences Inc. stock reacts to job market dataJuly 2025 Breakouts & Accurate Entry and Exit Point Alerts - Улправда
Jade Biosciences (NASDAQ:JBIO) Coverage Initiated at HC Wainwright - Defense World
Why Jade Biosciences Inc. stock is popular among millennialsQuarterly Portfolio Review & Daily Growth Stock Tips - Улправда
Will Jade Biosciences Inc. stock benefit from sector rotationPortfolio Performance Summary & Stepwise Trade Signal Implementation - Улправда
Why Jade Biosciences Inc. stock remains a top recommendationMarket Activity Report & Expert Approved Momentum Ideas - Улправда
Jade Biosciences (NASDAQ:JBIO) Upgraded to Strong-Buy at HC Wainwright - MarketBeat
H.C. Wainwright initiates coverage on Jade Biosciences stock with Buy rating - Investing.com India
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of Jade Biosciences (JBIO) with Buy Recommendation - Nasdaq
Institutional Investors of Jade Biosciences, Inc. (NASDAQ:JBIO) Must Be Disappointed After Last Week's 16% Drop - 富途牛牛
Does Jade Biosciences, Inc. (JBIO) have the potential to rally 65% as Wall Street analysts expect? - MSN
The recent drop in prices must have disappointed Jade Biosciences, Inc. (NASDAQ:JBIO) institutional investors who own 53% of the shares - simplywall.st
Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week - Yahoo Finance
Jade Biosciences outlines 2026 clinical pipeline and milestones By Investing.com - Investing.com Nigeria
Jade Biosciences (NASDAQ:JBIO) Shares Gap DownTime to Sell? - MarketBeat
Jade Biosciences Inc Stock (JBIO) Financials Data
There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):